DIHYDROQUERCETIN: PHARMACOLOGICAL PROPERTIES, POSSIBILITY OF USING THE DRUG IN CLINICAL PRACTICE
- Authors: Dedov D.V1,2
-
Affiliations:
- Tver State Medical University
- Tver Regional Clinical Cardiology Dispensary
- Issue: Vol 33, No 10 (2022)
- Pages: 78-80
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114712
- DOI: https://doi.org/10.29296/25877305-2022-10-16
- ID: 114712
Cite item
Abstract
The paper presented a scientific review of 19 publications by authors from the Netherlands, the Russian Federation, Great Britain, China, India, South Korea, the United States, Egypt, and Slovakia. We studied: the pharmacological properties of dihydroquercetin. Reflected the antioxidant, anti-inflammatory, antimicrobial, antitumor effects of Dihydroquercetin on the human body. Shown the prospects of using dihydroquercetine in clinical practice: in patients with cardiovascular diseases, with diabetes, in oncology, neurology, surgery, in COVID-19
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
D. V Dedov
Tver State Medical University; Tver Regional Clinical Cardiology Dispensary
Author for correspondence.
Email: dedov_d@inbox.ru
Professor, MD
Russian Federation,References
- Turck D., Bresson J.-L., Burlingame B. et al. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA Journal. 2017; 15 (2): 4682. DOI: 10.2903/j. efsa.2017.4682
- Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008; 585 (2-3): 325-37. doi: 10.1016/j.ejphar.2008.03.008
- Терехов Р.П. Влияние фазового состояния на физико-химические, технологические и биофармацевтические параметры дигидрокверцетина. Дисс.. канд. мед. наук. М., 2021; 173 с.
- Taldaev A., Terekhov R., Nikitin I. et al. Insights into the Pharmacological Effects of Flavonoids: The Systematic Review of Computer Modeling.Int J Mol Sci. 2022; 23 (11): 6023. doi: 10.3390/ijms23116023
- Weidmann A.E. Dihydroquercetin: More than just an impurity? Eur J Pharmacol. 2012; 684 (1-3): 19-26. doi: 10.1016/j.ejphar.2012.03.035
- Ковалевская Е.Г. Оптимизация условий производства субстанции дигидрокверцетина, разработка лекарственного препарата на ее основе. Автореф. дисс. канд. мед. наук. Пятигорск, 2014; 24 с.
- Sunil C., Xu B. An insight into the health-promoting effects of taxifolin (dihydroquercetin). Phytochemistry. 2019; 166: 112066. doi: 10.1016/j.phytochem.2019.112066
- Alam Q., Krishnamurthy S. Dihydroquercetin ameliorates LPS-induced neuroinflammation and memory deficit. Curr Res Pharmacol Drug Discov. 2022; 3: 100091. DOI: 10.1016/j. crphar.2022.100091
- Islam J., Shree A., Vafa A. et al. Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway.Int Immunopharmacol. 2021; 96: 107566. doi: 10.1016/j.intimp.2021.107566
- Jiang W., Wei H., He B. Dietary flavonoids intake and the risk of coronary heart disease: a dose-response meta-analysis of 15 prospective studies. Thromb Res. 2015; 135 (3): 459-63. doi: 10.1016/j.thromres.2014.12.016
- Kim Y., Je Y. Flavonoid intake and mortality from cardiovascular disease and all causes: A meta-analysis of prospective cohort studies. Clin Nutr ESPEN. 2017; 20: 68-77. doi: 10.1016/j.clnesp.2017.03.004
- Liu Y.J., Zhan J., Liu X.L. et al. Dietary flavonoids intake and risk of type 2 diabetes: a meta-analysis of prospective cohort studies. Clin Nutr. 2014; 33 (1): 59-63. DOI: 10.1016/j. clnu.2013.03.011
- Das A., Baidya R., Chakraborty T. et al. Pharmacological basis and new insights of taxifolin: A comprehensive review. Biomed Pharmacother. 2021; 142: 112004. DOI: 10.1016/j. biopha.2021.112004
- Chang S.C., Cassidy A., Willett W.C. et al. Dietary flavonoid intake and risk of incident depression in midlife and older women. Am J Clin Nutr. 2016; 104 (3): 704-14. DOI: 10.3945/ ajcn.115.124545
- Zhu Y., Scholle F., Kisthardt S.C. et al. Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E. Virology. 2022; 571: 21-33. doi: 10.1016/j.virol.2022.04.005
- Щукина О.Г. Экспериментальное исследование ранозаживляющих свойств дигидрокверцетина при термической травме кожи. Автореф. дисс.. канд. биол. наук. СПб, 2013; 28 с.
- Hassan M.A., Tamer T.M., Valachova K. et al. Antioxidant and antibacterial polyelectrolyte wound dressing based on chitosan/hyaluronan/phosphatidylcholine dihydroquercetin.Int J Biol Macromol. 2021; 166: 18-31. DOI: 10.1016/j. ijbiomac.2020.11.119
- Zhang J., Chen K., Ding C. et al. Fabrication of chitosan/PVP/dihydroquercetin nanocomposite film for in vitro and in vivo evaluation of wound healing.Int J Biol Macromol. 2022; 206: 591-604. doi: 10.1016/j.ijbiomac.2022.02.110
- Тюкавкина Н.А., Руленко И.А., Колесник Ю.А. Дигидрокверцетин - новая антиоксидантная и биологически активная пищевая добавка. Вопросы питания. 1997; 6: 12-5.
- Плотников М.Б., Логвинов С.В., Пугаченко Н.В. и др. Церебропротекторные эффекты смеси диквертина и аскорбиновой кислоты. Фармакология и токсикология. 2000; 130 (11): 543-7.
- Плотников М.Б., Тюкавкина Н.А., Алиев О.И. и др. Клиническая эффективность нового гемореологического препарата «Асковертин» у больных с дисциркуляторной энцефалопатией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004; 12: 33-7.
- Доровских В.А., Целуйко С.С., Симонова Н.В. и др. В мире антиоксидантов: учебное пособие. Благовещенск: Амурская государственная медицинская академия, 2012; 106 с.
- Бабкин В.А., Остроухова Л.А., Левчук А.А. и др. Влияние условий экстракции на выход нативного дигидрокверцетина, содержащего более 97% (+)-транс-изомера. Химико-фармацевтический журнал. 2017; 51 (1): 39-41.
- Xu Q., Parks C.G., DeRoo L.A. et al. Multivitamin use and telomere length in women. Am J Clin Nutr. 2009; 89 (6): 1857-63. doi: 10.3945/ajcn.2008.26986
Supplementary files
![](/img/style/loading.gif)